ZWJ Investment Counsel Inc. acquired a new stake in shares of Thermo Fisher Scientific Inc (NYSE:TMO) during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 47,080 shares of the medical research company’s stock, valued at approximately $7,231,000.
A number of other institutional investors also recently added to or reduced their stakes in TMO. C WorldWide Group Holding A S raised its stake in shares of Thermo Fisher Scientific by 997.1% in the first quarter. C WorldWide Group Holding A S now owns 1,950,049 shares of the medical research company’s stock worth $299,527,000 after buying an additional 1,772,300 shares during the last quarter. NN Investment Partners Holdings N.V. raised its stake in Thermo Fisher Scientific by 458.2% in the first quarter. NN Investment Partners Holdings N.V. now owns 528,598 shares of the medical research company’s stock worth $81,194,000 after buying an additional 433,898 shares in the last quarter. Swiss National Bank raised its position in shares of Thermo Fisher Scientific by 27.5% in the first quarter. Swiss National Bank now owns 1,399,732 shares of the medical research company’s stock valued at $214,999,000 after buying an additional 301,600 shares during the period. Karp Capital Management Corp bought a new position in shares of Thermo Fisher Scientific during the first quarter valued at approximately $46,008,000. Finally, Cornerstone Investment Partners LLC bought a new position in shares of Thermo Fisher Scientific during the first quarter valued at approximately $45,709,000. 87.60% of the stock is owned by institutional investors and hedge funds.
Thermo Fisher Scientific Inc (NYSE:TMO) traded down 0.19% during mid-day trading on Friday, hitting $172.57. The stock had a trading volume of 1,182,702 shares. Thermo Fisher Scientific Inc has a one year low of $139.07 and a one year high of $182.87. The company has a market cap of $67.32 billion, a PE ratio of 30.06 and a beta of 1.06. The firm’s 50-day moving average price is $176.71 and its 200 day moving average price is $166.56.
Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, July 26th. The medical research company reported $2.30 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.27 by $0.03. Thermo Fisher Scientific had a return on equity of 15.97% and a net margin of 11.80%. The company had revenue of $5 billion during the quarter, compared to analysts’ expectations of $4.92 billion. During the same period in the previous year, the firm posted $2.03 earnings per share. The business’s revenue for the quarter was up 10.2% compared to the same quarter last year. On average, equities research analysts anticipate that Thermo Fisher Scientific Inc will post $9.24 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Monday, October 16th. Stockholders of record on Friday, September 15th will be issued a $0.15 dividend. The ex-dividend date of this dividend is Thursday, September 14th. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.35%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.45%.
A number of analysts have recently weighed in on TMO shares. Zacks Investment Research raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $197.00 target price on the stock in a research report on Tuesday, August 1st. BidaskClub downgraded shares of Thermo Fisher Scientific from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Bank of America Corporation reissued a “buy” rating and set a $210.00 price objective (up from $200.00) on shares of Thermo Fisher Scientific in a research report on Friday, July 21st. Cleveland Research raised shares of Thermo Fisher Scientific from a “neutral” rating to a “buy” rating in a research report on Thursday, July 20th. Finally, Barclays PLC reaffirmed an “overweight” rating and set a $200.00 price target (up previously from $190.00) on shares of Thermo Fisher Scientific in a report on Monday, July 17th. One analyst has rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the stock. Thermo Fisher Scientific currently has an average rating of “Buy” and a consensus target price of $188.56.
In related news, CEO Marc N. Casper sold 20,000 shares of the company’s stock in a transaction on Thursday, June 1st. The stock was sold at an average price of $172.79, for a total value of $3,455,800.00. Following the completion of the transaction, the chief executive officer now directly owns 269,279 shares in the company, valued at $46,528,718.41. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jim P. Manzi sold 11,318 shares of the company’s stock in a transaction on Friday, August 18th. The shares were sold at an average price of $172.94, for a total value of $1,957,334.92. Following the completion of the transaction, the director now owns 38,757 shares of the company’s stock, valued at $6,702,635.58. The disclosure for this sale can be found here. Over the last three months, insiders sold 39,506 shares of company stock valued at $6,834,758. Insiders own 0.49% of the company’s stock.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
What are top analysts saying about Thermo Fisher Scientific Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Thermo Fisher Scientific Inc and related companies.